Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.
D000328:Adult; D001480:Basal Ganglia Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005069:Evaluation Studies as Topic; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007902:Length of Stay; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy; D008875:Middle Aged; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy*; D010919:Placebos; D012008:Recurrence; D012075:Remission, Spontaneous; D013375:Substance Withdrawal Syndrome; D013747:Tetrabenazine / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D014149:Tranquilizing Agents / Q000009:adverse effects
D010919:Placebos; D014149:Tranquilizing Agents; D006220:Haloperidol; D013747:Tetrabenazine